VTYX

Ventyx Biosciences, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website ventyxbio.com
Employees(FY) 99
ISIN US92332V1070

Performance

-8.2%

+25.84%

-5.49%

-18.55%

-9.31%

YTD

+7.69%

Profile

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.

Advanced Technical Analysis

Technical Analysis of VTYX 2024-12-20

The stock indicators reflect a predominantly bearish sentiment, with the Moving Average Score at 16 and the Technical Score at 28, both indicating weakness, while the Oscillators Score at 40 suggests a neutral stance. Overall, the combined scores point to a cautious outlook for the stock, highlighting potential challenges ahead.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of VTYX

Stock Rank

Recent News & Updates

2024-11-12 10:01
Ventyx Biosciences Reports Q3 Financial Results and Pipeline Progress(Yahoo Finance)
2024-11-11 18:30
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences(Globenewswire)
2024-11-07 03:05
Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress(Yahoo Finance)
2024-10-28 18:01
These 2 Strong Buy Penny Stocks Could Rally Over 500%, Say Analysts(Yahoo Finance)
2024-10-14 20:00
Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024(Globenewswire)
2024-09-23 01:54
Sanofi gains exclusivity rights to Ventyxs CNS-penetrant drug in $27m deal(Yahoo Finance)
2024-09-22 20:00
Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi(Globenewswire)
2024-09-05 20:00
Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's Disease(Globenewswire)
2024-08-29 20:00
Ventyx Biosciences Announces Departure of Chief Financial Officer(Globenewswire)
2024-08-29 19:04
Novo builds heart failure case for semaglutide; Ventyx CFO departs(Yahoo Finance)
2024-08-27 20:00
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences(Globenewswire)
2024-08-08 04:01
Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress(Globenewswire)
2024-07-30 05:13
Ventyx scraps TYK2 inhibitor after Phase II Crohns defeat(Yahoo Finance)
2024-07-28 20:00
Ventyxs TYK2 drug suffers second setback(Yahoo Finance)
2024-07-28 20:00
Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Participants with Moderately to Severely Active Crohn's Disease(Globenewswire)
2024-06-05 04:01
Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers(Globenewswire)
2024-05-16 04:05
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences(Globenewswire)
2024-05-15 23:23
Ventyx Biosciences Appoints Matthew Moore as Chief Operating Officer; Shares Rise(Yahoo Finance)
2024-05-15 20:00
Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer(Globenewswire)
2024-05-13 09:02
VTYX ALERT: Top Law Firm Bleichmar Fonti & Auld LLP Is Investigating the Directors of Ventyx Biosciences, Inc. for Potential Breaches of Fiduciary Duty; Contact the Firm for More Details(Newsfilecorp)
2024-05-12 22:37
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q1 2024 Earnings Call Transcript(Yahoo Finance)
2024-05-09 08:59
VTYX Stock Earnings: Ventyx Biosciences Beats EPS for Q1 2024(Investorplace)
2024-05-09 04:01
Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress(Globenewswire)
2024-05-02 04:05
Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024(Globenewswire)
2024-04-30 00:00
What Makes Ventyx Biosciences (VTYX) a New Buy Stock(Zacks)
2024-04-16 20:45
NASDAQ: VTYX Lawsuit Notice: Investors who lost over $100,000 with shares of Ventyx Biosciences, Inc. (NASDAQ: VTYX) should contact the Shareholders Foundation(Globenewswire)
2024-04-16 17:45
Ventyx Biosciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYX(Prnewswire)
2024-04-15 01:15
Investors who lost over $100,000 with Ventyx Biosciences, Inc. (NASDAQ: VTYX) between October 2021 to November 2023, should contact the Shareholders Foundation in connection with Lawsuit(Prnewswire)
2024-03-26 18:20
Investors in Ventyx Biosciences, Inc. Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYX(Prnewswire)
2024-03-19 17:45
Ventyx Biosciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYX(Prnewswire)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.